Data on acute myelomonocytic leukemia published by researchers at Nagoya University

01-12-2007

Data detailed in "Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication" have been presented. According to recent research from Nagoya, Japan, "We have established a stroma-dependent myelomonocytic cell line, NAMO-2, with FLT3 internal tandem duplication (FLT3/ITD). Leukemia cells from a patient with acute myelomonocytic leukemia were administered to form subcutaneous tumors in nude mice, which were maintained successively, although we failed to establish continuously growing cells from the original leukemia cell culture."

"In the cultures of cells from subcutaneous tumors, there were stroma cells that had originated from the nude mice and showed continuous growth. The leukemia cells showed continuous growth dependent on this stroma, and this cell line was named NAMO-2. Detection of FLT3/ITD by the reverse transcriptase polymerase chain reaction (PCR) and genomic PCR showed that NAMO-2 was homozygous for FLT3/ITD. Constitutive activation of FLT3 was detected by Western blotting, and the phosphorylation of Akt, MEK, and STAT5 was also observed. FLT3 kinase inhibitor AG1296 specifically inhibited cell growth," wrote A. Abe and colleagues, Nagoya University.

The researchers concluded: "NAMO-2 provides a useful tool to analyze adherence-dependent survival signaling of leukemia with FLT3/ITD and a model for the screening of FLT3 kinase inhibitors."

Abe and colleagues published their study in International Journal of Hematology (Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. International Journal of Hematology, 2006;84(4):328-36).

For additional information, contact A. Abe, Nagoya University Graduate School of Medicine, Dept. of Hematology and Oncology, Nagoya, Japan.

Publisher contact information for the International Journal of Hematology is: Carden Jennings Publ Co. Ltd., Blake Center, Ste. 200, 1224 W Main St., Charlottesville, VA 22903, USA.

Keywords: Japan, Nagoya, Acute Myelomonocytic Leukemia, Diagnosis, Diagnostics, Hematology, Monocytic Leukemia, Oncology.

This article was prepared by Hematology Week editors from staff and other reports. Copyright 2007, Hematology Week via NewsRx.com.



Related Diseases: Acute Myeloid Leukemia (AML)
Related Keywords: FLT3
Related Glossary Terms: AML
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Risk of leukemia with multiple sclerosis drug higher than thought
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia (AML)
Fewer platelets could be used for some cancer and bone-marrow transplantation patients
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Risk of leukemia with multiple sclerosis drug higher than thought
A miR boost enables acute leukemia cells to mature
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Azerra MAA Accepted by EMEA for CLL
Roche's MabThera approved in Europe for CLL
Chronic Myeloid Leukemia (CML)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Scientists Gain Insight Into Blood Cancer's Progression
Some blood-system stem cells reproduce more slowly than expected
Hodgkin Lymphoma
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Hodgkin lymphoma -- new characteristics discovered
Multiple Myeloma
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Green Tea May Negate the Benefits of Velcade
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Myelodysplastic Syndrome (MDS)
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Non-Hodgkin Lymphoma (NHL)
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Testicular Cancer
New Genes Linked to Testicular Cancer
Second gene linked to familial testicular cancer
Male Infertility Linked to Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer